Chapter

Neurosurgical Spasticity Treatment: From Lesion to Neuromodulation Procedures

José Damián Carrillo-Ruíz, Jesús Quetzalcoatl Beltran, José Rodrigo Carrillo-Márquez, José Luis Navarro-Olvera, Luis García, Francisco Villegas-López and Francisco Velasco

Abstract

Spasticity is one of the most important and residual signs after pyramidal and para-pyramidal catastrophic lesions after diverse neurological insults, including stroke, brain and spine trauma and post-radiation; infection and immunological diseases affecting nervous system, between others. Spasticity is normally a compensatory motor mechanism that could ameliorate the patients’ disability. Nevertheless, disastrous spasticity is described when the extremities force is diminished in the affected limbs, or when is impossible to wake or to take objects, maximum when hand or foot deformity is exposed. The objective of this chapter is centered in the neurosurgical treatment of spasticity, including brain lesions with specific targets and the spine with its different modalities. This review shows not only the basic aspects in these techniques, but also the option of infusion pumps and deep brain stimulation. To close, a proposal is stablished to determinate the possible path to treat the spasticity in the future.

Keywords: spasticity, neuroablation, neuromodulation, lesioning neurosurgery, motor disorders

1. Introduction

Spasticity is a motor disorder characterized by muscular hypertonia with resistance to passive movement, in a context of hyperexcitability of the stretch reflex. This disorder is a component of the upper motor neuron syndrome, an alteration where the inhibitory influence of supraspinal structures is lost. Spasticity is an important clinical problem frequently found in neurological patients. This condition is estimated to occur in 17–39% of patients with stroke [1], 37–78% of patients with multiple sclerosis [2], 65–78% of patients with spinal cord injury [3], and 90% of patients with cerebral palsy [4]. Spasticity could be very disabling for patients and its management requires several specialists and different therapeutic options.

If acceptable control of spasticity is not achieved with pharmacological treatment, physical therapy and rehabilitation, surgical procedures are the next treatment option. The goal of surgery in these patients is to decrease the excess muscle tone and rebalance agonist and antagonist muscle groups to improve function.
and limit deformities. To promote a better restoration of function in patients with spasticity, it is important to know the functional alterations of this disorder. Furthermore, in order to measure the effects on the pathology after some treatment, it is necessary to use classifications and scales. In the following sections, the first topic to be addressed is the neurophysiological alterations of spasticity and then it will be mentioned the scales with which the degree of affection is classified. Later, it is going to be described the neurosurgical procedures, both ablative and neuromodulatory, available to compensate for the physiological alterations of this disorder.

2. Spasticity: pathophysiology and classification

2.1 Pathophysiology of spasticity

Muscle tone depends on the intrinsic elasticity/stiffness of the muscle, and this in turn is modulated by the nervous system. In physiological conditions, the neural circuits in the spinal cord mediate muscle stretch reflexes. These local circuits also provide a mechanism to adjust muscle tone from supraspinal structures according to physiological requirements. Due to this configuration, lesions in these supraspinal structures or in the descending motor pathways are frequently associated with alterations in muscle tone. These alterations may involve an abnormal increase or decrease in tone. The most common form of hypertonia is spasticity, which is characterized by a velocity-dependent resistance to passive movement of a joint and its associated musculature. A slowly applied stretch in a patient with spasticity causes little resistance, but as the speed of the stretch increases, the stretch resistance also increases progressively. Thus, spasticity is primarily a phasic phenomenon. An active reflex contraction that occurs only during a rapid stretch; when the muscle is held in an elongated position, the reflex contraction decreases. However, in some cases hypertonia also has a tonic component, for example if reflex contractions persist even after the muscle is no longer stretched [5].

In the last years, the pathophysiology of spasticity has been increasingly understood. Stretch reflex hyperactivity was long thought to be caused by overactive gamma motor neurons. However, although gamma motor neurons may be overactive in some cases, changes in the background activity of alpha motor neurons and interneurons are probably more important. Particularly relevant seem to be modifications in the intrinsic properties of motor neurons that generate a sustained firing in response to a brief excitatory input. Another mechanism that produces spasticity is the strong facilitation of synaptic transmission in the sensory fiber of the monosynaptic reflex pathway. In fact, this provides a mechanism for treating this disorder. Currently, a relatively common therapeutic procedure favors presynaptic inhibition in the Ia fiber terminals by the intrathecal infusion of baclofen, a GABA-B receptor agonist, that blocks neurotransmitter release [5, 6].

2.2 Classification of spasticity

Classifying the severity and distribution of spasticity in each patient is an essential element to achieve effective treatment and to observe its response over time. The severity of this disorder can range from a focal problem with mild muscle stiffness to a severe and painful diffuse spasticity.

Based on its location, spasticity can be classified into Focal, Regional, and Generalized. In the first case, a single muscle group or part of the body is affected, in regional spasticity, adjacent muscle groups are affected in a region of the body. In the patients with generalized spasticity, all or almost all areas of the body are affected [6].
3. Spasticity assessment

The degree of affection, its evolution over time, and the response to the therapeutic options can be evaluated with the use of some scales. There are several widely used scales: Ashworth Scale (AS), Modified Ashworth Scale (MAS) and Gross Motor Function Classification System (GMFCS). They are formed of different points to construct ordinal scale that assess muscle tone. A higher score indicates a more intense spasticity [7].

Moreover, to comprehend correctly the information said before it is necessary to understand the meaning of two important concepts: spasticity and spasms. Spasticity is “hypertonia that is associated with one or both of the following signs: resistance to passive movement that increases with speed of stretch, or when the resistance to externally imposed movement rises rapidly above a threshold speed or joint angle” [8]. On the other hand, spasms can be defined as “episodes of involuntary motor contractions that occur following a lesion of the ascending motor pathway” [9]. It is important to mention that spasticity is detrimental to human health due to the miscommunication between the brain and the muscles, as a consequence those patients have a diminished quality of life. Spasms can be presented in long periods of time that is why problems in the musculoskeletal system can appear, affecting mobility and tone of posture.

Bryan Ashworth, in 1964, created a classification in which patients with multiple sclerosis could be graded in order of their clinical manifestations, starting to objectivize the knowledge of the pathology mentioned before [10]. Between the decades of 1960’s to late 1980’s the scale was used by doctors all over the world to help get a more accurate diagnose of spasticity, contributing to the progress of science in the field of neurology. Table 1 shows the classic Ashworth Scale that consist in five different types of categories that describe clinical manifestations of spasticity [11].

Furthermore, in 1987 Richard Bohannon’s group added to the scale a category “1+” for a more accurate classification regarding clinical manifestations in patients with spasticity. Since then, the scientific community has been using this scale of measure to add a more specific diagnose in patients that present rigid upper limb due to its extension [12]. It is important to mention that both scales, Ashworth and Modified Ashworth, are useful in the detection of spasticity and can be helpful to objectivize the manifestations of spasticity.

In this image, it can be seen the modifications that Richard Bohannon added to the Ashworth Scale (Table 2) [13].

Richard Penn has published several articles concerning spasticity, and also is attributed as the creator of a scale that measures the frequency of spasms “Penn Spasm Frequency Scale (PSFS)”.

Table 3 shows the different categories of spasms over time to identify characteristics according to the clinical manifestations [14].

| Scale | Description |
|-------|-------------|
| 0     | No increase in muscle tone. |
| 1     | Slight increase in muscle tone, manifested by a catch and release. |
| 2     | Marked increase in muscle tone throughout most of the range of motion, but affected part(s) easily move. |
| 3     | Considerable increase in muscle tone; passive movement difficult. |
| 4     | Affected part(s) rigid in flexion or extension. |

Table 1. Ashworth scale.
4. Treatment

The objective of the different pharmacological and surgical treatment options is to compensate the excitation/inhibition imbalance that occurs in the motoneurons of the ventral horn, the common final pathway for motor control. When possible, the underlying cause (e.g., tumor, abscess) that could be generated this imbalance should be eliminated. It is important to say that spasticity does not always require specific treatment. In many cases, spasticity can be helpful in maintaining balance and compensate for loss of motor power. Thus, spasticity should be treated when excess muscle tone leads to further functional disability, impaired locomotion, causes deformities, or induces chronic pain [5].

The different treatment options can be classified according to the location (focal vs. general) and duration (temporary vs. permanent) of their therapeutic effect. The choice of a treatment is made according to the severity and extent of spasticity and is adjusted according to the response and evolution of each patient. In general, surgical treatment is considered a second-line option, for patients with non-satisfactory response with drugs and physical therapy. Neurosurgical treatment options are divided into neuroablative and neuromodulatory procedures. The latter allow chemical or electrical regulation in the functioning of the neural circuits involved in spasticity. Importantly, such neuromodulation is characteristically adjustable and reversible. Ablative procedures are fixed and non-reversible. However, they still constitute a viable option for many patients, especially in those circumstances in which the use of neuromodulation equipment is not available. Figure 1 shows a general algorithm for the treatment of a patient with spasticity from its initial assessment to management with lesioning procedures. This algorithm is only a general guide, and in each patient the treatment should be individualized in the context of a multidisciplinary management.

| Scale | Description |
|-------|-------------|
| 0     | None        |
| 1     | Slight increase in muscle tone, manifested by a catch and release. |
| 1+    | Slight increase in muscle tone, manifested as a catch, followed through the remainder of the range of motion. |
| 2     | Marked increase in muscle tone throughout most of the range of motion, but affected part(s) easily move. |
| 3     | Considerable increase in muscle tone; passive movement difficult. |
| 4     | Affected part(s) rigid in flexion or extension. |

Table 2. Modified Ashworth scale (MAS).

| Scale | Description |
|-------|-------------|
| 0     | None        |
| 1     | Lack of spontaneous spasms; vigorous sensory and motor stimulation outcome in spasms. |
| 2     | Occasional spontaneous spasms occurring more than once per hour. |
| 3     | Greater than 1, but less than 10 spontaneous spasms per hour. |
| 4     | Greater than 10 spontaneous spasms per hour |

Table 3. Penn spasm frequency score (PSFS).
4.1 Ablative treatment

This treatment modality implies the realization of some injury in certain levels of the nervous system that participate in the motor function in order to counteract spasticity. These lesions include selective neurotomies, rhizotomies, DREZotomies,
myelotomies, and supramedular lesions. These procedures should be performed in such a way as to reduce excess muscle tone, but preserving residual sensorimotor functions and useful muscle tone. In cases of refractory spasticity, including paraplegic, hemiplegic or tetraplegic patients, the evolution and severity of the spasticity may require neuroablative management. In these cases, the injury procedure must be selective, and will be chosen considering the location of the spasticity (Figure 1). The characteristics of the most important and useful injuries will be reviewed below.

4.1.1 Selective neurotomy

Peripheral neurotomy was first introduced by Lorenz in 1887 for hip spasticity and by Stoffel in 1912 for spasticity in the foot [15]. This procedure consists of selectively identifying and injuring one motor nerve bundle that supply the spastic muscles. The goal of selective neurotomy is to inhibit the segmental reflex arc and thus limit the level of muscle spasticity. Selective neurotomy is indicated in cases of localized spasticity in a single or a few muscle groups, both in cases of focal or multifocal spasticity. The target nerves are selected according to the spastic region affected. Examples include lower subscapular nerve injury for spastic shoulder, median nerve injury for pronation spasticity of the upper limb, ulnar neurotomy for spastic wrist flexion with ulnar deviation, obturator nerve lesion in case of hip adduction spasticity, sciatic nerve for knee flexion spasticity and tibial neurotomy for equinus or equinovarus spastic foot [16].

The evaluation prior to neurotomy should include nerve blocks with a reversible agent such as botulinum toxin. These blocks allow us to observe a therapeutic effect previous to neurotomy and to evaluate its usefulness and acceptance. The injury must be performed with intraoperative electrophysiological monitoring of the nerve to be injured and must include 50–80% of the spastic muscle fibers to expect an effective result [5]. The most relevant long-term complications of the neurotomies are allodynia and neuropathic pain. To reduce the probability of the appearance of these adverse effects, it is important to identify and try to avoid sensory fibers during the procedure [17].

4.1.2 Selective dorsal rhizotomy

Sir Charles Sherrington, in 1898, showed that stiffness could be abolished by dorsal rhizotomy in a feline model with midbrain transection [18]. With this background, Otfrid Foerester, in 1913, reported the first dorsal rhizotomy for the management of lower limb spasticity in patients with cerebral palsy [19]. Rhizotomy consists of the selective section of the dorsal roots of the spinal nerve at a specific medullary level. It is thought that its effect is due to the reduction of the afferent information of the Ia fibers of the spastic muscle, which would produce a decrease in the excitatory input, and an increase in the inhibitory activity of the interneurons, to the alpha motoneurons [18, 19]. Dorsal rhizotomy is indicated in patients with diffuse or regional spasticity, in patients with spasticity in one or two limbs. There is no consensus on the precise selection criteria, but it is most frequently performed in paraplegic patients with spasticity in the lower extremities, however, it has also been performed successfully in the cervical region in patients with spasticity in the upper extremities [20, 21].

The procedure for the lower extremities is usually performed on the posterior roots of L1-S2 levels, exposed with a laminectomy or laminoplasty. For spasticity of the upper extremities, rhizotomy has been described from C1-C3 levels, not sectioning dorsal root of C4 to avoid affecting the diagrammatic function [20, 21]. Similar to neurotomies, it is important to perform intraoperative electrophysiological mapping to identify the roots that contribute to spasticity. In cases of pediatric
cerebral palsy, it has been observed that the patients with the greatest improvement are those between 4 and 7 years old and have a preoperative gross motor function measure test (GMFM-88) between 65–85% [22]. The most important side effects of this procedure are impaired sensation, sphincter dysfunction, cerebrospinal fluid fistula, and chronic low back pain [17]. Techniques with more limited and selective lesions have been tried to improve the results and reduce the probability of the appearance of side effects [7].

4.1.3 DREZotomy

This procedure was initially performed by Sindou, in 1972, for the surgical treatment of pain. He observed that this technique also produced important hypotonia in the muscles corresponding to the severed medullary segment, and suggested its application in cases of spasticity [23, 24]. This surgery is similar to rhizotomy, but the injury here is made in the spinal cord, at the Dorsal Root Entry Zone (DREZ). The underlying mechanism in this case, is a disruption of Ia afferent inputs to the dorsal horn and a disruption of local circuits that contribute to muscle tone [6]. This procedure is indicated in cases of severe regional spasticity, especially those associated with pain and poor or no regional function, such as in paraplegic or hemiplegic patients with painful hyperspasticity or severe spasms [25, 26]. The surgery, which requires an intradural approach and adequate visualization of the posterior surface of the spinal cord, consists of 3-mm deep incision at the dorsolateral sulcus, down to the dorsal horn, following its axis. When spasticity is associated with focal dystonia, DREZotomy should be more deeply down to the base of the ventral horn [5]. DREZotomy can be performed at the C5-C8 medullary levels (at 35° angle) for the management of spasticity in the upper extremities or at L1-S2 levels (at 45° angle) for the lower extremity affection. The most important complications of this technique are damage to the pyramidal pathway with loss of strength and severe hypotonia, so it should be considered in patients with severe refractory spasticity who have little residual function in the limb.

4.1.4 Longitudinal myelotomy

Bischof originally described the longitudinal myelotomy in 1951, and it was subsequently performed more selectively by Pourpre in 1960, and by Laitinen & Singounas in 1971 [8, 27, 28]. This procedure consists of a frontal separation between the ventral and dorsal horns at the level of the lumbosacral enlargement. The goal of surgery is to interrupt the spinal reflex arc by severing the connection between the posterior and anterior horns of the spinal cord. Through a T9-L1 laminectomy or laminoplasty, the procedure is performed at the T11-S2 medullary levels. Once the spinal cord is exposed, a posterior longitudinal sagittal incision is made deep to the central canal prior to performing a transverse cut using a stylet with a right-angled extremity, to separate the ventral and dorsal horns [7]. This surgery has been used in the treatment of patients with paraplegia, especially in cases with triple flexion and loss of sphincter function [6].

4.1.5 Other procedures

Some stereotaxic procedures in the thalamus and cerebellum have been performed for the treatment of spasticity in selected cases. These lesioning procedures include ventrolateral thalamotomy, pulvinarotomy, dentatotomy, and lesion of nucleus fastigii [29]. Due to the complexity, risks and lack of better effectiveness compared to the surgical options for spinal cord and peripheral nerve, these procedures were abandoned [6].
On the other hand, orthopedic surgery is another lesioning option. Neurosurgical procedures are the first choice for the management of spasticity and dystonia, but orthopedic surgery is a complementary surgical option for cases in which spasticity persists after neurosurgical treatment. Orthopedic surgery can reduce spasticity by releasing or lengthening tendons in the affected region. Orthopedic procedures may be indicated primarily when contractures and ankylosises are predominant or like the last option when the deformity is so strong [6].

4.2 Neuromodulation treatment

The classic procedures to treat spasticity are focused to perform lesions or ablative brain, spinal or nerve surgeries, but in recent times it exists the opportunity of neuromodulation. This term involved the use of chemical or electric pulses to increase or decrease neuron threshold with the main goal to diminish or abolish neurological or/and psychiatry symptoms. Neuromodulation is widespread to treat neuropathic and phantom pain, movement disorders abnormalities like Parkinson's disease, essential tremor and dystonia; partial and generalized epilepsy; obsessive–compulsive disorder, depression or anorexia; motor problems of neurogenic bladder, and neurologic deafness and blindness.

In this sense, neuromodulation in spasticity is concerned mainly to the use of infusion pumps, treatment acknowledged all over the world. Nevertheless, it exists the possibility to utilize electric stimulation in two targets: spinal cord and cerebellar sites to ameliorate the stiffness limb, but is not spread like infusion pumps.

4.2.1 Infusion pumps in spasticity

The next lines are dedicated to resume the infusion pump in the treatment of spasticity. It should be said that there is no cure to spasticity, but different methods and treatments can be useful. Infusion pumps are generally described as: “Complicated electromechanical systems that are used to deliver anesthetic drugs with moderate precision” [30]. Regarding neurosciences, different drugs are used in order to help patients with spasticity and other similar illnesses, mainly baclofen. Since 1984, the usage of infusion pumps with baclofen was proposed by Richard Penn due to prior scientific evidence that this chemical could work as an analogue of “γ-aminobutyric acid” (GABA) in its B receptor, how it is mentioned [31].

Humans can be treated effectively with intrathecal baclofen to decrease drastically the symptoms, and the burden that this illness means. Baclofen is a GABAergic drug that is transmitted intrathecally by infusion to the subarachnoid space. Although baclofen can be taken orally, the quickness and effectiveness of the chemical is decreased in comparison with the utilization of pumps to treat patients with spasticity. When taken orally, baclofen can have as a maximum dosage approximately 360 mg per day, but when infused intrathecally the dosage reduces to approximately 250–500 μg per day. Although, Baclofen is a very effective chemical it also has some repercussions like muscle weakness and slowness in walking speed due to the effects that induces, but they can be controlled if the dose is adequate for the patient (Table 4) [32].

Overall, the experience of scientists and neurosurgeons using intrathecal baclofen can be described as a positive one, but most important good results have been shown for patients with spasticity. In Table 4, it can be seen how several authors have been using this technique to improve the development of the pathology. The former table contains twelve different categories in which all the authors present the results obtained by the research. In the “year” column it can be seen when the paper was published, and in the “number of patients” the amount of people that took participation in the research. In general, the “follow-up” period
| Number | Author            | Year | No. patients | Follow-up “months” | % improvement | Ashworth PRE | Ashworth POP | Other Scale PRE | Other scale POP | Baclophen’s Dose | Other Dose |
|--------|-------------------|------|--------------|--------------------|---------------|--------------|--------------|----------------|----------------|----------------|------------|
| 1      | R D Penn          | 1989 | n = 20       | 19.2(10–33)        | 70%           | 4(1)         | 1.2(0.4)     | NS             | NS             | 100–150 μg/day | NS         |
| 2      | P. G. Loubser     | 1991 | n = 9        | 3–22              | 69.31%        | 3.78(1.34)   | 1.16 (0.48)  | Reflex: 3.57(1.05) | Reflex: 0.64(0.87) | 535.8(269) μg/day | NS         |
| 3      | R. Becker         | 1996 | n = 18       | 13–54             | 48%           | 4.5          | 2.33         | PSFS: 2.16      | PSFS: 0.94      | 265 μg/day     | NS         |
| 4      | Alexei I. Korenko | 2002 | n = 12       | 12                | 48%           | 4.2          | 2.2          | NS             | NS             | 180 (65–280) μg/day | NS         |
| 5      | Daniel Guillaume  | 2005 | n = 138      | 12                | 51.24%        | 4.02(0.92)   | 1.96(0.78)   | NS             | NS             | 288 μg/d      | NS         |
| 6      | Giulia Stampacchia| 2016 | n = 14       | 12                | 86%           | 3.5          | 0.5          | NS             | NS             | 250.5(187.5) μg/day | NS         |
| 7      | Tanja Kraus       | 2017 | n = 13       | 60 (12–100)       | 55.26%        | 3.8          | 1.7          | NS             | NS             | According patients’ needs: pediatrics | NS         |
| 8      | Mithra B Maneyapanda | 2017 | n = 42      | 36                | NS            | NS           | NS           | NS             | Functional Independence: 13 (33%) | 605.89(333.1) μg/day | NS         |
| 9      | Elke Pucks-Faes   | 2018 | n = 116      | 64.4(40.7)        | 50%           | 4            | 2            | NS             | NS             | 152.7(76.8) μg/day | NS         |
| 10     | Pedro Videira Reis| 2019 | n = 155      | 96 (9–132)        | 79%           | 4(3–4)       | 1(1–2)       | PSFS: 4(3–4)    | PSFS: 1(0–1)   | 230(95 to 400) μg/day | NS         |

Table 4. Comparison between authors according to baclofen treatment in this table it has been merged information from different articles that inform about intrathecal baclofen usage [14]; [33–41]. NS = not specified.
was variant, but the tendency as years pass is determined to give the patient a longer period between the follow-up in comparison with the older papers. It should be said, that when analyzing the Ashworth Scale comparing the preoperatory and the post-operatory, results show that using intrathecal baclofen can help reduce drastically the stiffness to a slight increased muscle tone in the majority of the patients.

Regarding the "dose", the difference between pediatric and adult treatment should be addressed to understand how to apply intrathecal pumps. Some factors in children may affect the treatment, that is why there should be a pediatrician involved in the process of treating infants in order to apply the correct dosage and time to realize the pump implantation, and do not interfere with their development. In adults, it can be said that covering a good dosage is easier because developed organisms can receive intrathecal treatments better with doses from 200–600 $\mu$g/day. Moreover, due to biological variability different patients need more baclofen if they are still showing symptoms of spasticity, and less in the case of having problems with movement and also muscle weakness; that is why the doctor should be ready to evaluate when to adjust the dose of the drug according to patients’ requirements.

Authors with long number of participants tend to have similar results, that is why it is important to have a correct number of participants and dose to generate a more accurate investigation. The dose of those investigations with more than a hundred participants express that the amount of baclofen needed to help a patient can approximately be 220 $\mu$g/day as a good reference to start the drug’s usage. Although, none of the authors used another drug in their papers it should be said that baclofen is an effective chemical that can help patients with spasticity infused intrathecally. Also, it is important that doctors have to analyze correctly the dose for a better performance of the pump in each individual, and avoid toxicity problems (Figures 2–6).

In the following years, neurosurgeons and their teams have been adding information to the methods and the correct usage of this technique, gathering approximately 35 years of experience in the field of infusion pumps and the usage of baclofen in order to treat spasticity.

**4.2.2 Spinal cord stimulation**

The first person who used SCS in the treatment of an illness was Shealy when he was neurosurgery resident in the 60’s decade. In the 50’s, the original idea was emerged after the use of battery connected to cardiac electrodes located in the animal’s atrium and modified the myocardial electricity in the treatment of arrhythmias. After an experimental period, the use of a voltaic pile and heart electrodes brings the first pacemaker in man, and established one of the most important medical knowledge about implants in the human being until now.

Shealy thought this principle of pacemakers, first in dogs and after in humans, could be used in neurologic patients. He took the first patients with uncontrolled pain cancer, and he implanted in the spinal cord, a system similar to the cardiac patients. The results are the amelioration of pain. Indeed, in this moment Shealy was opened the door to Neuromodulation at the neurologic patients [42, 43].

With respect to spasticity, based in the experience of Shealy with SCS for pain treatment in 1973, Cook and Wenstein reported one Multiple Sclerosis (MS) patient with pain alleviation but with the fortuitous finding that also limb spasticity amelioration was presented [44]. In 1976, Illis in UK introduced percutaneous electrodes in two MS patients and peridural space was stimulated and improved spasticity [45]. In 1979, Richardson and cols wrote an article with six spastic patients, in which spasticity was measure by a scale similar to Ashworth, with 36.11% of improvement, and also for first time the article described SCS
electric parameters of stimulation (Voltage from 0.5 to 2 V, frequency 33 to 75 HZ, and pulse width of 100 to 200 μsec) [46]. In 1980, Read and cols reported 16 MS patients: 9 had spasticity amelioration, 3 without change and 2 had worst evolution with increase in spasticity; the total alleviation was 56.25% in the group [47]. In the same year, Siegfried showed his experience with originally 26 patients using test stimulation before definitive implantation, consisting in percutaneous electrodes and depending if the test was positive, they implanted a definitive one. Only 11 patients were operated and followed 3 years with amelioration of the spasticity. Best results depending of spinal and partial damage more than cerebral site of spasticity. They also used electrophysiological measures like H-reflex to contrast the amelioration [48]. Also, in this year, Dimitrijevic showed the results of 11 patients with spasticity that improved 56.56% after SCS, mainly clonus and EMG patterns. In 1985, Barolat-Romana reported 6 spasticity patients with spasms and the immediate alleviation after SCS [49]. In 1986, Dimitrijevic and cols studied 59 patients in which spasticity was reduced in 63% of the group. They found spasticity was controlled better if the electrode was located below the spinal lesion more than above, also patients had better results with partial lesion that with complete ones [50]. In 1986, the same group with Campos (like the first author) described 8 patients with minimal function of posterior columns, 90% responded to the
epidural stimulation [51]. In 1988, Barolat made a clinical trial expanded the initial experience to 16 myelopathic subjects with amelioration of spasm and clonus, inclusive from one year of follow-up [52]. In 1993, the same group was amplified the experience of 509 plates implanted in patients suffered pain and spasticity: 350 in the whole group, 227 for pain, 105 for motor disturbances (spasms/spasticity following spinal cord or cranial trauma, multiple sclerosis, cerebral palsy, spasmatic torticollis and other motor problems) and 18 patients with both condition: pain and spasticity. From these, 3.4% had infection, 1.1% with electrode migration and less of 1%, breakage [53]. In the decade of 1990’s it existed poorly advanced in this area. In 2000, Pinter and Dimitrijevic discovered that severe spasticity in paraplegic patients could improve with the electrode’s position upper to the spinal lesion, with frequency of 50–100 Hz, 2–7 Volts and 210 μsec and adapted depended of the case [54]. In 2015, Dekopov and Russian team evaluated two groups of spasticity patients: Cerebral palsy and spinal cord lesion. SCS ameliorated Ashworth scale (58.8%) in cerebral palsy group, but it did not for the spinal cord lesion [55].

Figure 3.
It is demonstrated how the pump should be implanted, so as the stitch used in order to seal the neck of the gadget with the catheter.
4.2.3 Cerebellar stimulation

The understanding of cerebellar human stimulation began in the experiments developed in rats, cats, dogs and monkeys. It was based in these antecedent that Cooper and cols in 1973 located electrodes on the anterior and posterior surface of cerebellum to treat not only spasticity, but seizures also [56–58]. After these reports, Cooper and his group contribute significantly to this neuromodulation area with different types of articles including implantation technique, clinic evolution, surgical complications, neurophysiological changes, psychological reactions, between other issues [59–64]. Other groups started to perform CS. In 1977, Manrique and cols implanted 4 patients with good results to diminished spasticity [65], Penn found in some patients diminished spasticity and, in other, no changes [66, 67]. Cooper’s work was continued by Davis [68–73] spreading the experience in this field. In 2003 and 2007, respectively, Galanda & Horvath proposed new insights about CS [74, 75]. In the last decade there has been no progress in this area.
Figure 5.
Post-operative picture of the pump immediately after the implantation surgery. X-ray image must be taken to verify the correct placement of the equipment.

Figure 6.
X-ray image shows the infusion pump implanted in the lower part of the left hypochondria. The red arrow indicates the catheter connected to the infusion pump, and the tip goes to T-10 level into the subarachnoid space.
5. Post-surgery considerations

After any surgical procedure, physical therapy and recovery are very important. There is no consensus on the duration and specific type of rehabilitation that should be followed. There is great variability in the literature, but some authors recommend close follow-up to 3 months after hospital convalescence [16]. The physical therapy and rehabilitation protocols must be adapted to each patient, and so should be emphasized that is crucial to promote functional improvement after surgical management. The results and their functional impact on patients can be seen in variable times, and the follow-up should be at least for 6 months. All management and follow-up of the patient with spasticity should be carried out, whenever possible, by a multidisciplinary team to promote the best results, as well as avoid possible problems [5].

6. Other techniques and targets

Recently, it exists other possibilities to treat spasticity. It is only mentioned to avoid extend this review. For one side, magnetic transcranial or spinal stimulation. These techniques mean the performance of a coil connected to an electric source to produce electromagnetic waves modifying the brain’s plasticity: primary motor cortex or cerebellar cortex are the selected targets; or in an experimental manner in spinal circuitry.

On the other hand, electrical transcutaneous stimulation over the limb or spinal cord try to ameliorate also spasticity. It is remarkable that neurosurgical procedures in spasticity are the second line of treatment, when rehabilitation maneuvers were excluded. After the surgery has been performed the use of physical exercises is mandatory. To finish, it should be said that orthopedic procedures must be done when the extremities are deformed.

Conflict of interest

The authors declare no conflict of interest.

Author details

José Damián Carrillo-Ruíz1,2*, Jesús Quetzalcoatl Beltran1, José Rodrigo Carrillo-Márquez2, José Luis Navarro-Olvera1, Luis García1, Francisco Villegas-López1 and Francisco Velasco1

1 Stereotactic and Functional Neurosurgery Unit, Mexico General Hospital, Mexico City, Mexico

2 Faculty of Health Sciences, Anahuac Mexico University, Mexico City, Mexico

*Address all correspondence to: josecarrilloruiz@yahoo.com

IntechOpen

© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References

[1] Brainin M, et al. “Poststroke chronic disease management: towards improved identification and interventions for poststroke spasticity-related complications,” Int J Stroke 2011; 6 (1):42-46.

[2] Barnes M P, Kent R M, Semlyen J K, McMullen K M. “Spasticity in multiple sclerosis,” Neurorehab Neural Repair 2003; 17 (1): 66-70.

[3] Adams M M, Hicks A L. “Spasticity after spinal cord injury,” Spinal Cord 2005; 43 (10): 577-586.

[4] Yeargin-Allsopp M, Braun K V N, Doernberg N S, Benedict R E, Kirby R S, Durkin M S. “Prevalence of cerebral palsy in 8-year-old children in three areas of the United States in 2002: a multisite collaboration,” Pediatrics 2008; 121(3): 547-554.

[5] Sindou M, Georgoulis G, Mertens P. “Lesioning surgery for spasticity,” in Youmans and Winn Neurological Surgery, 7th ed., M. H. Richard Winn, Ed. Elsevier 2017: 716-728.

[6] Sindou M, Georgoulis G, Mertens P. Neurosurgery for Spasticity: A Practical Guide for Treating Children and Adults. Springer 2014.

[7] Sindou M, Mertens P. “Destructive neurosurgical procedures for spasticity,” in Textbook of Stereotactic and Functional Neurosurgery, R. Lozano, Andres M. Gildenberg, Philip. Tasker, Ed 2009.

[8] Laitinen L, Singounas E. “Longitudinal myelotomy in the treatment of spasticity of the legs” J Neurosurg 1971; 35(5): 536-540.

[9] Sanger TD, Delgado MR, Gaebler-Spira D, Hallett M, Mink JW. Classification and definition of disorders causing hypertonia in childhood. Pediatrics 2003; 111(1): 89-97.

[10] Khurana SR, Garg DS. Spasticity and the use of intrathecal baclofen in patients with spinal cord injury. Phys Med Rehab Clin 2014; 25(3):655-669.

[11] Ashworth B. Preliminary Trial of Carisoprodol in Multiple Sclerosis. Practitioner 1964; 192: 540-542. PMID: 14143329.

[12] Harb A, Kishner S. Modified Ashworth Scale. StatPearls. Treasure Island (FL): StatPearls Pub 2020; https://www.ncbi.nlm.nih.gov/books/NBK554572/

[13] Bohannon R W, Smith M B. Interrater Reliability of a Modified Ashworth Scale of Muscle Spasticity, Phys Tx 1987; 67 (2):206-207, https://doi.org/10.1093/ptj/67.2.206

[14] Penn RD, Savoy SM, Corcos D, Latash M, Gottlieb G, Parke B, Kroin JS. Intrathecal baclofen for severe spinal spasticity. NEJM 1989; 320 (23): 1517-1521.

[15] Stoffel A. “The treatment of spastic contractures”. Am J Orthop Surg 1912; 10: 611-644.

[16] Madsen P J, Chen H-C I, Lang S-S “Neurosurgical Approaches”. Phys Med Rehab Clin 2018; 29(3): 553-565.

[17] Siththinamsuwan B, Nunta-Aree S. “Ablative neurosurgery for movement disorders related to cerebral palsy”. J Neurosurg Sci 2015; 59(4): 393-404.

[18] Sherrington CS. “Decerebrate rigidity, and reflex coordination of movements”. J Physiol 1898; 22(4): 319.

[19] Foerster O. “On the indications and results of the excision of posterior spinal nerve roots in men”. Surg Gynecol Obs 1913; 16: 463-475.

[20] Kottke FJ. “Modification of athetosis by denervation of the tonic neck
Neurosurgical Spasticity Treatment: From Lesion to Neuromodulation Procedures
DOI: http://dx.doi.org/10.5772/intechopen.96054

reflexes,” Dev Med Child Neurol 1970; 12(2); 236.

[21] Heimburger R F, Slominski A, Griswold P. “Cervical posterior rhizotomy for reducing spasticity in cerebral palsy”. J Neurosurg 1973; 39(1): 30-34.

[22] Funk J F, et al. “Predictors for the benefit of selective dorsal rhizotomy”. Res Dev Disabil 2015; 37: 127-134.

[23] Sindou M. “Étude de la jonction radiculo-médullaire postérieure, la radicellotomie postérieure sélective dans la chirurgie de la douleur”. Impr HM 1972.

[24] Sindou M, G Fischer, R Goutelle, B Schott, Mansuy, “La radicellotomie postérieure selective dans le traitement des spasticites”. Rev Neurol 1974; 30: 201-215.

[25] Sindou M, Mifsud J J, Boisson D, A. Goutelle. “Selective posterior rhizotomy in the dorsal root entry zone for treatment of hyperspasticity and pain in the hemiplegic upper limb”. Neurosurgery 1986; 18(5): 587-595.

[26] Sindou M, Jeanmonod D. “Microsurgical DREZ-otomy for the treatment of spasticity and pain in the lower limbs”. Neurosurgery 1989; 24(5): 655-670.

[27] Pourpre M H. “Traitemnt neurochirurgical des contractures chez les paralplégiques post-traumatiques”. Neurochirurgie 1960; 6: 229-236.

[28] W. Bischof, “Die longitudinale myelotomie,” Zentralbl Neurochir 1951; 11: 79-88.

[29] Siegfried J. “Destructive stereotatic procedures for spasticity directed to the brain and the cerebellum” Ed Springer. Neurosurgery for Spasticity 1991; 187-190.

[30] Mandel JE. Understanding Infusion Pumps. Anesthesia & Analgesia 2018; 1, 126(4): 1186-9.

[31] Penn R, Kroin J. Intrathecal baclofen alleviates spinal cord spasticity. Lancet 1984; 1(8385): 1078.

[32] Ghai A, Garg N, Hooda S, Gupta T. Spasticity–Pathogenesis, prevention and treatment strategies. Saudi journal of anaesthesia 2013; 7(4):453-460.

[33] Loubser PG, Narayan RK, Sandin KJ, Donovan WH, Russell KD. Continuous infusion of intrathecal baclofen: long-term effects on spasticity in spinal cord injury. Spinal Cord 1991; 29(1):48-64.

[34] Becker R, Alberti O, Bauer BL. Continuous intrathecal baclofen infusion in severe spasticity after traumatic or hypoxic brain injury. J Neurol 1997; 244(3):160-166.

[35] Korenkov AI, Niendorf WR, Darwish N, Glaeser E, Gaab MR. Continuous intrathecal infusion of baclofen in patients with spasticity caused by spinal cord injuries. Neurosurgical rev 2002; 25(4):228-230.

[36] Guillaume D, Van Havenbergh A, Vlooberghs M, Vidal J, Roeste G. A clinical study of intrathecal baclofen using a programmable pump for intractable spasticity. Archives of physical medicine and rehabilitation 2005; 86(11): 2165-2171.

[37] Stampacchia G, Gerini A, Mazzoleni S. Effects of severe spasticity treatment with intrathecal Baclofen in multiple sclerosis patients: Long term follow-up. Neuro Rehabilitation 2016; 38(4): 385-393.

[38] Kraus T, Gegenleitner K, Svehlik M, Novak M, Steinwender G, Singer G. Long-term therapy with intrathecal baclofen improves quality of life in children with severe spastic cerebral palsy. Eu J Paediatr Neurol 2017; 21(3): 565-569.

[39] Maneyapanda MB, McCormick ZL, Marciniak C, Reger C. Long-term dosing
of intrathecal baclofen in the treatment of spasticity after acquired brain injury. PM&R 2017; 9(6): 556-562.

[40] Pucks-Faes E, Matzak H, Hitzenberger G, Genelin E, Halbmayer LM, Fava E, Fritz J, Saltuari L. Intrathecal Baclofen Trial Before Device Implantation: 12-Year Experience with Continuous Administration. Arch Phys Med Rehabil 2019; 100(5): 837-843.

[41] Reis PV, Vieira CR, Midões AC, Rebelo V, Barbosa P, Gomes A. Intrathecal Baclofen Infusion Pumps in the Treatment of Spasticity: A Retrospective Cohort Study in a Portuguese Centre. Acta Médica Portuguesa 2019; 32(12):754-759.

[42] Shealy CN, Mortimer JT, Reswick JB. Electrical inhibition of pain by stimulation of the dorsal columns: preliminary clinical report. Anesth Analg 1967; 46(4): 489-491.

[43] Shealy CN, Taslitz N, Mortimer JT, Becker DP Electrical inhibition of pain: experimental evaluation. Anesth Analg 1967; 46(3): 299-305.

[44] Cook AW, Weinstein SP. Chronic dorsal column stimulation in multiple sclerosis. Preliminary report. N Y State J Med 1973; 73(24): 2868-2872.

[45] Illis LS, Oygar AE, Sedgwick EM, Awadalla MA. Dorsal-column stimulation in the rehabilitation of patients with multiple sclerosis. Lancet 1976; 1 (7974):1383-1386. doi: 10.1016/s0140-6736(76)93030-0

[46] Richardson RR, Cerullo LJ, McLone DG, Gutierrez FA, Lewis V. Percutaneous epidural neurostimulation in modulation of paraplegic spasticity. Six case reports. Acta Neurochir (Wien) 1979; 49(3-4): 235-243. doi: 10.1007/BF01808963.

[47] Read DJ, Matthews WB, Higson RH. The effect of spinal cord stimulation on function in patients with multiple sclerosis. Brain 1980; 103(4): 803-833. doi: 10.1093/brain/103.4.803.

[48] Siegfried J. Treatment of spasticity by dorsal cord stimulation. Int Rehabil Med 1980; 2(1): 31-34. doi: 10.3109/09638288009163952.

[49] Barolat-Romana G, Myklebust JB, Hemmy DC, Myklebust B, Wenninger W Immediate effects of spinal cord stimulation in spinal spasticity. JNS 1985; 62(4): 558-562. doi: 10.3171/jns.1985.62.4.0558.

[50] Dimitrijevic MM, Dimitrijevic MR, Illis LS, Nakajima K, Sharkey PC, Sherwood AM. Spinal cord stimulation for the control of spasticity in patients with chronic spinal cord injury: I. Clinical observations. Springer. Cent Nerv Syst Trauma 1986; 3(2): 129-144. doi: 10.1089/cns.1986.3.129.

[51] Campos RJ, Dimitrijevic MR, Sharkey PC, Sherwood AM. Epidural spinal cord stimulation in spastic spinal cord injury patients. Appl Neurophysiol 1987; 50(1-6): 453-454. doi: 10.1159/000100763.

[52] Barolat G, Myklebust JB, Wenninger W. Effects of spinal cord stimulation on spasticity and spasms secondary to myelopathy. Appl Neurophysiol 1988; 51(1): 29-44. doi: 10.1159/000099381.

[53] Barolat G. Experience with 509 plate electrodes implanted epidurally from C1 to L1. Stereotact Funct Neurosurg 1993; 61(2): 60-79. doi: 10.1159/000100624.

[54] Pinter MM, Gerstenbrand F, Dimitrijevic MR. Epidural electrical stimulation of posterior structures of the human lumbosacral cord: 3. Control Of spasticity. Cord 2000; 38(9): 524-531. doi: 10.1038/sj.sc.3101040.

[55] Dekopov AV, Shabalov VA, Tomsky AA, Hit MV, Salova EM. Chronic
Spinal Cord Stimulation in the Treatment of Cerebral and Spinal Spasticity. Stereotact Funct Neurosurg 2015; 93(2):133-139. doi: 10.1159/000368905.

[56] Cooper IS. Effect of chronic stimulation of anterior cerebellum on neurological disease. Lancet 1973; 1(7796): 206. doi: 10.1016/s0140-6736(73)90042-1.

[57] Cooper IS. Effect of stimulation of posterior cerebellum on neurological disease. Lancet. 1973; 1(7815): 1321. doi: 10.1016/s0140-6736(73)91338-x.

[58] Cooper IS, Crighel E, Amin I. Clinical and physiological effects of stimulation of the paleocerebellum in humans. J Am Geriatr Soc. 1973; 21(1): 40-43. doi: 10.1111/j.1532-5415.1973.tb00849.x.

[59] Upton AR, Cooper IS. Some neurophysiological effects of cerebellar stimulation in man. Can J Neurol Sci. 1976; 3(4): 237-254. doi: 10.1017/s031716710002535x.

[60] Riklan M, Cullinan T, Shulman M, Cooper IS. A psychometric study of chronic cerebellar stimulation in man. Biol Psychiatry 1976; 11(5): 543-574.

[61] Cooper IS, Amin I, Upton A, Riklan M, Watkins S, McLellan L. Safety and efficacy of chronic stimulation. Neurosurgery 1977; 1(2): 203-205. doi: 10.1097/00006123-197709000-00019.

[62] Riklan M, Cullinan T, Cooper IS. Tension reduction and alerting in man following chronic cerebellar stimulation for the relief of spasticity or intractable seizures. J Nerv Ment Dis 1977; 164(3): 176-181. doi: 10.1097/00005053-197703000-00003.

[63] McLellan DL, Selwyn M, Cooper IS. Time course of clinical and physiological effects of stimulation of the cerebellar surface in patients with spasticity. Neurol Neurosurg Psychiatry 1978; 41(2): 150-160. doi: 10.1136/jnnp.41.2.150.

[64] Cooper IS, Upton AR, Amin I. Chronic cerebellar stimulation (CCS) and deep brain stimulation (DBS) in involuntary movement disorders. Appl Neurophysiol 1982; 45(3): 209-217. doi: 10.1159/000101601.

[65] Manrique M, Oya S, Vaquero J, Lozano AP, Herrero J, Bravo G. Chronic paleocerebellar stimulation for the treatment of neuromuscular disorders. Four case report. Appl Neurophysiol 1978; 41(1-4): 237-247. doi: 10.1159/000102423.

[66] Penn RD, Gottlieb GL, Agarwal GC. Cerebellar stimulation in man. Quantitative changes in spasticity. J Neurosurg 1978; 48(5): 777-786. doi: 10.3171/jns.1978.48.5.0779.

[67] Fisher MA, Penn RD. Evidence for changes in segmental motoneurone pools by chronic cerebellar stimulation and its clinical significance. J Neurol Neurosurg Psychiatry 1978; 41(7): 630-635. doi: 10.1136/jnnp.41.7.630.

[68] Davis R, Flitter MA. Cerebellar stimulation. Surg Neurol 1978; 9(2): 115.

[69] Davis R, Barolat-Romana G, Engle H. Chronic cerebellar stimulation for cerebral palsy—five-year study. Acta Neurochir Suppl (Wien) 1980; 30:317-332. doi: 10.1007/978-3-7091-8592-6_39.

[70] Davis R, Engle H, Kudzma J, Gray E, Ryan T, Dusnak A. Update of chronic cerebellar stimulation for spasticity and epilepsy. Appl Neurophysiol 1982; 45(1-2): 44-50. doi: 10.1159/000101577.

[71] Davis R, Schulman J, Nanes M, Delehanty A. Cerebellar stimulation for spastic cerebral palsy—double-blind quantitative study. Appl Neurophysiol 1987; 50(1-6): 451-452. doi: 10.1159/000100762.
[72] Davis R. Cerebellar stimulation for cerebral palsy spasticity, function, and seizures. Arch Med Res 2000; 31(3): 290-9. doi: 10.1016/s0188-4409(00)00065-5.

[73] Davis R. Twenty-eight years of clinical experience with implantable neuroprotheses for various applications. Artif Organs 2002; 26(3):280-283. doi: 10.1046/j.1525-1594.2002.06937.x.

[74] Galanda M, Horvath S. Effect of stereotactic high-frequency stimulation in the anterior lobe of the cerebellum in cerebral palsy: a new suboccipital approach. Stereotact Funct Neurosurg 2003; 80(1-4): 102-107. doi: 10.1159/000075168.

[75] Galanda M, Horvath S. Stereotactic stimulation of the anterior lobe of the cerebellum in cerebral palsy from a suboccipital approach. Acta Neurochir Suppl 2007; 97(2): 239-243. doi: 10.1007/978-3-211-33081-4_27.